Exosomes in pancreatic juice as valuable source of biomarkers for early diagnosis of pancreatic cancer

2017 ◽  
Vol 6 (S8) ◽  
pp. S1339-S1351 ◽  
Author(s):  
Zarin Nuzhat ◽  
Carlos Palma ◽  
Gregory E. Rice ◽  
Virendra Joshi ◽  
Carlos Salomon
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Pancreatic Juice ◽  
Valuable Source

Sa1509 Clinical Values of Cytodiagnosis Using Pancreatic Juice Multiple Times via Endoscopic Nasopancreatic Drainage for Early Diagnosis of Pancreatic Cancer

2016 ◽  
Vol 83 (5) ◽  
pp. AB278 ◽  
Author(s):  
Tomoyuki Minami ◽  
Keiji Hanada ◽  
Naomichi Hirano ◽  
Akihito Okazaki ◽  
Yoshihiro Izumi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Pancreatic Juice ◽  
Endoscopic Nasopancreatic Drainage ◽  
Nasopancreatic Drainage

scholarly journals Endoscopic Ultrasonography Diagnosis of Early Pancreatic Cancer

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1086
Author(s):  
Keisuke Kurihara ◽  
Keiji Hanada ◽  
Akinori Shimizu
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Endoscopic Ultrasonography ◽  
Pancreatic Juice ◽  
Early Stage ◽  
Survival Rates ◽  
Stage I ◽  
Pancreatic Tumors ◽  
High Detection Rate ◽  
Pancreatic Juice Cytology

Early diagnosis of pancreatic cancer (PC) can improve patients’ prognosis. We aimed to investigate the utility of endoscopic ultrasonography (EUS) for the early diagnosis of PC. This study included 64 patients with PC at an early stage treated at Onomichi General Hospital between January 2007 and January 2020. Diagnostic procedures included contrast computed tomography (CT), magnetic resonance cholangiopancreatography, EUS fine-needle aspiration, and endoscopic retrograde cholangiopancreatography (ERCP) for pancreatic juice cytology. The mean age was 71.3 years. In all, 32 patients were stage 0, and 32 were stage I. As for image findings, the main pancreatic duct (MPD) stenosis was detected in several cases, although CT and MRCP seldom detected tumors. EUS had a high detection rate for stage 0 tumor lesions. The median observation period was 3.9 years. In cases with stage 0, the 1 year and 5 year survival rates were 100% and 78.9%, respectively. In cases with stage I, the 1 year and 5 year survival rates were 96.4% and 66.7%, respectively. EUS has the highest sensitivity among all imaging modalities for detecting small pancreatic tumors. Cases with MPD dilation or stenosis, especially with tumors that cannot be identified on CT and MRI, should have EUS performed. In some cases, EUS was not able to detect any tumor lesions, and ERCP-based pancreatic juice cytology should be useful for pathological diagnosis.

scholarly journals A Proteomic Study on the Personalized Protein Corona of Liposomes. Relevance for Early Diagnosis of Pancreatic DUCTAL Adenocarcinoma and Biomarker Detection

2021 ◽  
Vol 2 (2) ◽  
pp. 82-93
Author(s):  
Luca Digiacomo ◽  
Francesca Giulimondi ◽  
Daniela Pozzi ◽  
Alessandro Coppola ◽  
Vincenzo La Vaccara ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Protein Corona ◽  
Detection Sensitivity ◽  
Ductal Adenocarcinoma ◽  
Protein Biomarkers ◽  
Ca 19.9 ◽  
Proteomic Study

Due to late diagnosis, high incidence of metastasis, and poor survival rate, pancreatic cancer is one of the most leading cause of cancer-related death. Although manifold recent efforts have been done to achieve an early diagnosis of pancreatic cancer, CA-19.9 is currently the unique biomarker that is adopted for the detection, despite its limits in terms of sensitivity and specificity. To identify potential protein biomarkers for pancreatic ductal adenocarcinoma (PDAC), we used three model liposomes as nanoplatforms that accumulate proteins from human plasma and studied the composition of this biomolecular layer, which is known as protein corona. Indeed, plasma proteins adsorb on nanoparticle surface according to their abundance and affinity to the employed nanomaterial, thus even small differences between healthy and PDAC protein expression levels can be, in principle, detected. By mass spectrometry experiments, we quantified such differences and identified possible biomarkers for PDAC. Some of them are already known to exhibit different expressions in PDAC proteomes, whereas the role of other relevant proteins is still not clear. Therefore, we predict that the employment of nanomaterials and their protein corona may represent a useful tool to amplify the detection sensitivity of cancer biomarkers, which may be used for the early diagnosis of PDAC, with clinical implication for the subsequent therapy in the context of personalized medicine.

scholarly journals Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1986
Author(s):  
Victoria Heredia-Soto ◽  
Nuria Rodríguez-Salas ◽  
Jaime Feliu
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Practice ◽  
Early Diagnosis ◽  
Minimally Invasive ◽  
Liquid Biopsy ◽  
Genetic Material ◽  
Current Status ◽  
Ductal Adenocarcinoma ◽  
Disease Monitoring ◽  
Global Status

Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for detecting and monitoring PDAC.

New‐onset Diabetes as a Harbinger of Pancreatic Cancer: is Early Diagnosis Possible?

2021 ◽  
pp. 409-417
Author(s):  
Dana K. Andersen ◽  
Suresh T. Chari ◽  
Eithne Costello ◽  
Tatjana Crnogorac‐Jurcevic ◽  
Phil A. Hart ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Onset Diabetes ◽  
New Onset

Mo1401 Serum Metabolomics As the Diagnostic Application for Early Diagnosis of Pancreatic Cancer

2013 ◽  
Vol 144 (5) ◽  
pp. S-657
Author(s):  
Takashi Kobayashi ◽  
Shin Nishiumi ◽  
Atsuki Ikeda ◽  
Tomoo Yoshie ◽  
Aya Sakai ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Early Diagnosis ◽  
Diagnostic Application ◽  
Serum Metabolomics
Sign in / Sign up

Export Citation Format

Share Document